Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06712316 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by BioNTech SE.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,260
- Enrollment target
- 20
- Study locations
NCT06712316 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by BioNTech SE. The registered enrollment target is 1,260 participants, above the 656-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT06712316, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by BioNTech SE.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,260 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Pumitamig
Study Locations (20)
Ohio
- Gabrail Cancer Center Research - Canton
- The Christ Hospital Cancer Center - Cincinnati
- University of Cincinnati Medical Center - Cincinnati
- The Cleveland Clinic Cancer Center At Fairview Hospital, Moll Pavilion - Cleveland
- Cleveland Clinic - Cleveland
Florida
- Clermont Oncology Center - Clermont
- Cleveland Clinic Florida - Martin North Hospital - Stuart
- H. Lee Moffit Cancer center and research institute - Tampa
- Cleveland Clinic Weston Hospital - Weston
Iowa
- Physicians Clinic of Iowa - Cedar Rapids
- Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics - Iowa City
New Jersey
- Astera Cancer Care - East Brunswick
- The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion - Paramus
Alaska
- Alaska Oncology and Hematology, LLC - Anchorage
Kentucky
- Baptist Health Hardin - Elizabethtown
Maryland
- Frederick Health Hospital- James M Stockman Cancer Institute - Frederick
Missouri
- SSM Health Cancer Care - St. Clare - Fenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,260 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2030-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06712316
The ClinicalTrials.gov registry entry for NCT06712316 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,260 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 656-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% higher). The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06712316 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Ohio, Florida, Iowa.
Frequently Asked Questions
What is clinical trial NCT06712316 about?
NCT06712316 is a clinical study titled "Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer". This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice...
What is the current status of trial NCT06712316?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,260 participants. The study started on 2025-01-07. Estimated completion is 2030-03.
What conditions does trial NCT06712316 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06712316?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Pumitamig (DRUG).
Who is sponsoring clinical trial NCT06712316?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06712316 being conducted?
This trial has 20 study locations across Alaska, Florida, Iowa, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.